In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on CervoMed (CRVO – Research Report), with a price target of $15.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Soumit Roy has given his Buy rating due to a combination of factors surrounding CervoMed’s strategic developments and potential market opportunities. The company is advancing its Phase 3 study for neflamapimod in dementia with Lewy bodies (DLB), with plans to initiate the trial in mid-2026. This follows a potential meeting with the FDA in late 2025, where the company aims to present comprehensive data that could allow them to proceed directly to Phase 3. The high unmet need in DLB treatment suggests that the FDA might approve the advancement, which could positively impact the stock.
Additionally, CervoMed’s cash position is projected to support operations until mid-2026, although further fundraising might be necessary if additional trials are required. The company is also exploring other therapeutic areas, such as ischemic stroke and primary progressive aphasia, which could diversify its portfolio and enhance its market potential. These strategic initiatives, coupled with promising preliminary data from earlier trials, underpin Soumit Roy’s optimistic outlook on CervoMed’s future performance.
According to TipRanks, Roy is an analyst with an average return of -28.5% and a 16.97% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Elicio Therapeutics, and Chimerix.
In another report released on May 13, Roth MKM also reiterated a Buy rating on the stock with a $20.00 price target.